Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MI HARRISSONS > Asthma > Flashcards

Asthma Flashcards

1
Q

is a syndrome characterized by airflow obstruction that varies markedly, both spontaneously and with treatment.

A

Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

approximately ____ of adults and ____ of children affected by the disease.

A

10–12% adults

15% children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Major risk factors for asthma deaths are

A
  1. poorly controlled disease with frequent use of bronchodilator inhalers
  2. lack of or poor compliance with ICS therapy
  3. previous admissions to hospital with near-fatal asthma.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Endogenous Risk factors for ASTHMA

A 
Genetic predisposition 
ATOPY
airway hyperresponsiveness 
Gender
Ethnicity 
Obesity
Early viral infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Environmental Risk factors for ASTHMA

A 
Indoor allergens
Outdoor allergens
Occupational sensitizers
Passive smoking 
Respiratory infections
Diet
Acetaminophen (PARACETAMOL)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Asthma TRIGGERS

A 
Drugs (BB & ASA)
Allergens
URT viral infx 
Exercise and hyperventilation
Cold air
Sulfur dioxide and irritant gases
Stress
Irritants (paints, sprays)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mast cells release several bronchoconstrictor mediators including :

A

histamine
prostaglandin D2
cysteinyl-leukotrienes

several cytokines, chemokines, growth factors, and neurotrophins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

____ is an upstream cytokine released from epithelial cells of asthmatics that orchestrates the release of chemokines that selectively attract TH2 cells.

A

TSLP

Thymus stimulated lymphopoeitin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Th2 cytokines that mediates allergic inflammation

A

IL-4
IL-5
IL -13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pro-inflammatory cytokines that amplify the inflammatory response and play a role in more severe disease

A

TNF-a

IL-1b

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Inflammatory mediators

A

histamine
prostaglandin D2
cysteinyl-leukotrienes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Inflammatory mediators (histamine
prostaglandin D2
cysteinyl-leukotrienes)

A

Contract airway smooth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Asthma can present at any age, with a peak age of

A

3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

is the major risk factor for asthma

A

Atopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

This is rarely useful in clinical practice, but can be used in the differential diagnosis of chronic cough and when the diagnosis is in doubt in the settingof normal pulmonary function tests.

A

The increased AHR is normally measured by methacholine or histamine challenge with calculation of the provocative concentration that reduces FEV1 by 20% (PC20).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

is now being used as a noninvasive test to measure eosinophilic airway inflammation. The typically elevated levels in asthma are reduced by ICS, so this may be a test of compliance with therapy. It may also be useful in demonstrating insufficient anti-inflammatory therapy and may be useful in down-titrating ICS.

A

Fractional exhaled nitric oxide (FENO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

act primarily on airway smooth muscle to reverse the bronchoconstriction of asthma

A

Bronchodilators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Gives rapid relief of symptoms but has little or no effect on the underlying inflammatoryprocess. Thus, are not sufficient to control asthma inpatients with persistent symptoms.

A

bronchodilators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

True or false

Anticholinergic are less effective than β2-agonists in asthma therapy as they inhibit only the cholinergic reflex component of bronchoconstriction, whereas β2-agonists prevent ALL bronchoconstrictor mechanisms.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

These effects may account For the reduction in AHR that is seen with chronic ICS therapy.

A

ICS reduce eosinophils in the airways and sputum, and numbers of activated T lymphocytes and surface mast cells in the airway mucosa.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

ICS are nowgiven as first-line therapy for patients with persistent asthma, butif they do not control symptoms at low doses, it is usual to add a _____ as the next step

A

LABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

is a depot preparation that is Occasionally used in noncompliant patients, but proximal myopathy is a major problem with this therapy.

A

IM triamcinolone acetonide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

are asthma Controller drugs that appear to inhibit mast cell and sensory nerve activation and are, therefore, effective in blocking trigger-induced asthma such as EIA and allergen- and sulfur dioxide-induced symptoms.

A

Cromolyn sodium and nedocromil sodium or cromones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

is a blocking antibody that neutralizes circulating IgE without binding to cell-bound IgE and, thus, inhibitsIgE-mediated reactions

A

Omalizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

markedly reduce blood and tissue eosinophils and reduce exacerbations in patients who have persistentlyincreased sputum eosinophils despite maximal ICS therapy.

A

Anti-IL-5 Antibodies that block IL-5

mepolizumab, reslizumab) or-it’s receptor (benralizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

is a bronchoscopic treatment using thermal energy to ablate airway smooth muscle in accessible bronchi. It may reduce exacerbations and improve asthma control in highly selected patients not controlled on maximal inhaler therapy, particularly when there is no increase in inflammation.

A

Bronchial thermoplasty

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

True or false:
Anti-IL-13 blocking antibodies have little clinical effect, but-an antibody (dupilumab) against the common receptor for IL-4 and IL-13 (IL-4Rα) is more promising in reducing exacerbations and improving asthma control in severe asthma

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

A course of OCS (usually prednisone or prednisolone ____ once daily for 5–10 days) is usedto treat acute exacerbations of asthma; no tapering of the dose isneeded

A

30–45 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What dose is used For mild to moderate exacerbations, using repeated administrations of INHALED SABA is an effective and efficient way to achieved rapid reversal of airflow limitation.

A

4-10 puffs SABA every 20mins for the first hour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

The recommended dose of OCS for adults is

A

1mg prednisolone/kg/day

Or equivalent up to a maximum of 50mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

OCS should usually be continued for how many days

A

5-7days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What are the SABA?

A

Saba AT

Albuterol
Terbutaline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What are the LABA?

A

LABAS F

Salmeterol
Formeterol

34
Q

What are the ANTICHOLINERGICS?

A

ITsANTICHOLINERGICS

Ipratropium
Tiotropim

35
Q

What are the oral corticosteroids?

A

Prednisone

Prednisolone

36
Q

What are the ICS?

A

FLUTICASONE

BUDESONIDE

37
Q

What are the relievers or Bronchodilators?

A

Beta 2 agonists SABA LABA
Anticholinergic ITS
Theophylline (aminophylline)

38
Q

MOA OF B2 agonists

A

Inhibition of mast cell mediator release
Reduction in PLASMA EXUDATION
Inhibition of SENSORY NERVE ACTIVATION

NO EFFECT: dec of AHR & inflammation

39
Q

Discharge management:

Patients currently prescribed ICS containing medication should generally have their treatment stepped up for how many days

A

2-4weeks

40
Q

Discharge management:

Prescribe OCS at least now many days and dosages?

A

5-7 day course of OCS

Prednisone or equivalent 40-50mg / day

41
Q

If the OCS is DEXAMETHASONE, how many days of treatments post discharge?

A

1-2days

42
Q

The FEV1/FVC ratio is normally more than ____ in adults, and more than 0.85 in children.

A

0.75–0.80

43
Q

FEV1 increases by >200mL and >12% of the baseline value (or in children, increases by >12% of the predicted value) after inhaling a bronchodilator. This is called

A

bronchodilator reversibility

44
Q

Evidence of variability of expiratory airFlow limitation:

FEV1 increases by more than 12% and 200mL from baseline (in
children, by >12% of the predicted value) after

A 
4 weeks of anti-
inflammatory treatment (outside respiratory infections
45
Q

True or false:

Bronchodilator reversibility may be absent during severe exacerbations or viral infections. If bronchodilator reversibility is not present when it is first tested, the next step depends on the clinical urgency and the availability of other tests.

A

True

46
Q

What is the role of lung function in monitoring asthma?

Once asthma has been diagnosed, lung function is most useful as an indicator of future risk. It should be recorded at

A

diagnosis,

3–6 months after starting treatment, and periodically thereafter.

47
Q

Over-use of SABA (e.g. ≥3 canisters dispensed in a year) is associated with an increased risk of severe exacerbations, and dispensing of ___ canisters in a year is associated with increased risk of asthma-related death.

A

≥12

48
Q

given intravenously or by nebulizer is effective when added to Inhaled β2-agonists, and is relatively well tolerated but is not routinely recommended.

A

Magnesium sulfate

49
Q

The preferred treatment in step 1 in patient’s who have symptoms less than twice a month

A

As needed Low dose ICS + formoterol (LABA)

50
Q

Off label controller options at step 1

A

Low dose ICS taken whenever SABA is taken

51
Q

Preferred controller in step 2

A

DAILY low dose ICS plus as needed SABA

Off label: As needed low dose ICS-FORMOTEROL (LABA)

52
Q

True or false:

Daily low dose of ICS + LABA as initial therapy leads to faster improvement in symptoms and FEV1 than ICS ALONE but more costly and the exacerbation rate is similar

A

True

53
Q

Preferred controller in step 3

A

Low dose ICS-LABA maintenance plus as needed SABA

or

Low dose ICS FORMOTEROL maintenance and reliever therapy

54
Q

For adult patients with rhinitis who are allergic to house dust mite, consider adding — provided FEV1 is >70% predicted

A

sublingual immunotherapy (SLIT)

55
Q

When should patient follow up after starting treatment?

A

Patient should preferably be seen at 1-3 months after starting treatment and every 3-12 months after that.

56
Q

When should pregnant patient follow up after starting treatment?

A

In pregnancy, asthma should be reviewed every 4-6 weeks

57
Q

In a well controlled asthma, Step down thru available formulations to reduce the ICS dose by 25-50% is done at how many months of interval?

A

2-3 months

58
Q

If asthma is well controlled on low dose ICS or LTRA, what is a step down option?

A

As needed Low dose ICS -formeterol

59
Q

Value of FEV1/FVC that is diagnostic of obstruction?

A

<70%

60
Q

Value of total lung capacity that defines restrictive pathophysiology

A

<80%

61
Q

Although most patients with asthma are easily controlled with appropriate medication, a small proportion ofpatients (~5%) are difficult to control despite maximal inhaled therapy

A

Refractory Asthma

62
Q

It is defined by a failure to respond to a high dose of oral prednisone/prednisolone (40 my once daily over 2 weeks), ideally with a 2-week run-in with matched placebo

A

Corticosteroid-Resistant Asthma

63
Q

Some patients show chaotic variations in lung function despite taking appropriate therapy. Some show a persistent pattern of variability and may require OCS or, at times, continuous infusion of β2-agonists

A

type I brittle asthma

64
Q

generally normal or near-normal lung function but precipitous, unpredictable falls in lung function that may result in death

A

type 2 brittle asthma

65
Q

The most effective therapy in brittle asthma, which suggests that the worsening islikely to be a localized airway anaphylactic reaction with edema

A

subcutaneous epinephrine

66
Q

In Pregnancy, drugs that have been used for many years in asthma therapy have now been shown to be safe and without teratogenic potential. Thesedrugs include

A

SABA, ICS, and theophylline

67
Q

If an OCS is needed, it is better to use this drug rather Than prednisolone as it cannot be converted to the active prednisolone by the fetal liver, thus protecting the fetus from systemic effects

A

prednisone

68
Q

In asthma,a patients undergoing surgery,Patients who are treated with OCS will have adrenal suppression and should be treated with an___ dose of OCS immediately prior to surgery.

A

increased

69
Q

For patients with mild, intermittent asthma, what meds is all that is required

A

SABA

70
Q

The treatment of choice for all patients is an ___ give twice daily.

A

ICS

71
Q

Seen in 10% of patients, normal serum IgE, later onset, commonly with nasal polyps, may be ASA sensitive, usually more severe persistent asthma, increased local production of IgE In The airways

A

Intrinsic asthma

72
Q

Implicated antigen in intrinsic asthma

A

Staphylococcal enterotoxin

73
Q

Airway edema + acute infallmatory response with increased eosinophils and neutrophils that is not reversible with bronchodilators

A

Late phase allergic reaction

74
Q

In exercise induced asthma the best prevention is

A

Regular tx with ICS

Other prevention: B2 agonist and antileukotrienes

75
Q

Environmental air pollutants that inc asthma symptoms

A

Ozone
NO2
So2 sulfur dioxide
Diesel particulate

76
Q

Characteristic pathological finding in asthma

A

Thickening of the basement membrane due to subepithelila COLLAGEN deposition

77
Q

Inflammation of the respiratory mucosa extends from the trachea to the terminal bronchioles with the PREDOMINACE of inflammation located at the?

A

BRONCHI (cartilaginous airway)

78
Q

What is the physiologic abnormality is asthma

A

Airway hyperresponsiveness AHR

79
Q

Inflammatory mediators released by mast cells

A

Histamine

Cysteinyl leukotrienes

80
Q

Asthma is associated with a specific chronic inflammation of the mucosa of the

A

lower airways.

MI HARRISSONS (62 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions